Evidence map›Paper›PMID 39306595›Full record

Observational studyHeart and vessels2025

Clinical advantages of reduced expiratory positive airway pressure setting in adaptive servo-ventilation therapy.

Teruhiko Imamura, Yoshihiro Fukumoto, Hitoshi Adachi, Shin-Ichi Momomura, Yoshio Yasumura, Takayuki Hidaka, Takatoshi Kasai, Koichiro Kinugawa, Yasuki Kihara, the SAVIOR-L investigators

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Heart and vessels, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Teruhiko ImamuraSecond Department of Internal Medicine, Toyama University, 2630 Sugitani, Toyama, 930-0194, Japan. teimamu@med.u-toyama.ac.jp.ORCID http://orcid.org/0000-0002-7294-7637
Yoshihiro FukumotoDivision of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School, Kurume, Japan.
Hitoshi AdachiDivision of Cardiology, Gunma Prefectural Cardiovascular Center, Maebashi, Gunma, Japan.
Shin-Ichi MomomuraDepartment of Medicine, Saitama Citizens Medical Center, Saitama, Japan.
Yoshio YasumuraDepartment of Cardiology, Amagasaki Chuo Hospital, Amagasaki, Japan.
Takayuki HidakaDepartment of Cardiovascular Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Takatoshi KasaiDepartment of Cardiovascular Biology and Medicine and Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Koichiro KinugawaSecond Department of Internal Medicine, Toyama University, 2630 Sugitani, Toyama, 930-0194, Japan.
Yasuki KiharaDepartment of Cardiovascular Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
the SAVIOR-L investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical ramifications of adaptive servo-ventilation (ASV) therapy have stirred debate within the medical community. Given the potential detrimental effect of elevated expiratory positive airway pressure (EPAP) on cardiac output, we hypothesized that relatively lower EPAP may be recommended for successful ASV therapy. In-hospital patients with congestive heart failure refractory to medical therapy were included in the prospective cohort study of ASV therapy on prognosis in repeatedly hospitalized patients with chronic heart failure: longitudinal observational study of effects on readmission and mortality (SAVIOR-L) study. Assignment to either the ASV treatment group or the medical management group was at the discretion of the attending physicians. For the purposes of this retrospective study, our focus remained solely on the ASV cohort. We conducted an extensive analysis to elucidate the influence of lower EPAP settings on midterm mortality. A total of 108 patients were included. The median age was 74 years, and 83 (77%) patients were male. The median EPAP setting employed was 4 cmH

Indexed as

Heart FailurePositive-Pressure RespirationAgedAged, 80 and overFemaleHumansMaleMiddle AgedPatient ReadmissionRetrospective StudiesTime FactorsTreatment OutcomeHeart failureHemodynamicsNon-invasive positive pressure support

Identifiers

PMID39306595

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.